ReviewBrain sciences2022
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06882122 (Neurophysiological and Biomolecular Effects of Atogepant in High Frequency Episodic Migraine), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neurophysiological and Biomolecular Effects of Atogepant in High Frequency Episodic Migraine (ATOM Project)
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review.The journal of headache and pain · 2026Pooled it
- Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.The journal of headache and pain · 2024Pooled it
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.Neurology and therapy · 2026Article
- Chronic Migraine Resistance: A Case Report Highlights an Overlooked Factors in Family Medicine Clinics.Healthcare (Basel, Switzerland) · 2026Article
- Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Neuroinflammation and RAMP1: the Role of the Peripheral and Central Nervous System in Tumor Progression.Cell biochemistry and biophysics · 2026Review
- A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women.Headache · 2026Article
- Predicting Pharmacological Treatment Response in Migraine Using AI/ML: A Scoping Review of the Evidence and Future Directions.Pharmacotherapy · 2026Review
- A review on gut microbiota and migraine severity: a complex relationship.Inflammopharmacology · 2026Review
- Integrative Migraine Therapy: From Current Concepts to Future Directions-A Plastic Surgeon's Perspective.Medicina (Kaunas, Lithuania) · 2025Review
- A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.The journal of headache and pain · 2025Article
- Exploring the epigenetic modifications of the RONS-TRPA1-CGRP axis in migraine pathophysiology.The journal of headache and pain · 2025Review
- PACAP versus CGRP in migraine: From mouse models to clinical translation.Cephalalgia : an international journal of headache · 2025Review
- Gepants: Key Features of A Potent Therapeutic Option and Considerations in The Latin American Context.Revista de neurologia · 2025Review
- Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system.The journal of headache and pain · 2025Article
- Migraine with and without aura-two distinct entities? A narrative review.The journal of headache and pain · 2025Review
- A comprehensive review on calcitonin gene-related peptide in the management of gastrointestinal disorders.Inflammopharmacology · 2025Review
- Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine.Drug design, development and therapy · 2025Article
- MetaCGRP is a high-precision meta-model for large-scale identification of CGRP inhibitors using multi-view information.Scientific reports · 2024Article
- Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.The journal of headache and pain · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known as gepants. CGRP antagonists were the first oral agents specifically designed to prevent migraines. The second generation of gepants includes rimegepant (BHV-3000, BMS-927711), ubrogepant (MK-1602), and atogepant (AGN-241689, MK-8031). Zavegepant (BHV-3500, BMS-742413) belongs to the third generation of gepants characterized by different administration routes. The chemical and pharmacological properties of this new generation of gepants were calculated. The clinical trials showed that the new generation of CGRP antagonists is effective for the acute and/or preventive treatment of migraines. No increased mortality risks were observed to be associated with the second- and third-generation gepants. Moreover, the majority of the serious adverse events reported probably occurred unrelated to the medications. Interesting facts about gepants were highlighted, such as potency, hepatotoxicity, concomitant use with monoclonal antibodies targeting the CGRP, comparative analysis with triptans, and the "acute and preventive" treatment of migraine. Further studies should include an elderly population and compare the medications inside this class and with triptans. There are still concerns regarding the long-term side effects of these medications, such as chronic vascular hemodynamic impairment. Meanwhile, careful pharmacovigilance and safety monitoring should be performed in the clinical practice use of gepants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.